Daré Bioscience, Inc. reported earnings results for the third quarter ended September 30, 2023. For the third quarter, the company reported revenue was USD 1 million. Net loss was USD 8.3 million compared to USD 7.02 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.36 USD | +14.29% | +17.23% | +16.50% |
05-15 | Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3 | MT |
05-14 | Transcript : Daré Bioscience, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.50% | 31.68M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- DARE Stock
- News Daré Bioscience, Inc.
- Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023